KPTI — Karyopharm Therapeutics Inc.
Is KPTI overbought or oversold? Here is the current MarketMoodz read.
Karyopharm Therapeutics Inc. (KPTI) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.03. The rating moved from Oversold to Strong Oversold on November 4, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.03
- Last changeMoved from Oversold to Strong Oversold on November 4, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Karyopharm Therapeutics Inc. shows characteristics of a high-risk, small-cap biotech: a very low share price, limited visible liquidity, and reliance on binary clinical/regulatory outcomes. Current sector flows favor large-cap, defensive pharma and reduce investor appetite for speculative names, while convertible-debt and financing themes heighten dilution risk for mid‑cap biotech issuers. Absent clear positive clinical updates, strong cash runway disclosure, or evident investor interest, downside risk and volatility are likely to remain elevated. Monitoring near-term financing plans, upcoming clinical/regulatory milestones, and any changes in trading liquidity is critical to reassess the firm’s outlook.
Key factors
- Extremely low market capitalization and share price indicating severe market skepticism and limited investor liquidity.
- Biotech company profile with binary clinical and regulatory catalysts; valuation is highly sensitive to trial/regulatory outcomes.
- Sector backdrop favors large-cap pharma and defensive names, reducing investor appetite for small/mid-cap biotech risk.
- Convertible-debt and financing pressure is a sector theme that typically raises dilution risk for issuers like Karyopharm.
- Lack of recent positive social or EDGAR/filing signals in the provided data increases informational opacity.
- Limited short-term macro/sector tailwinds specifically supporting small, high-risk biotech equities in the current market narrative.
Risks
- High dilution risk from future equity or convertible financings that could materially impair existing shareholders.
- Clinical trial failures or regulatory setbacks that would likely cause further steep de-rating.
- Liquidity and trading-volume risk that can amplify price moves and impede orderly exits for holders.
- Potential for delisting or exchange compliance issues if market cap, share price or filing obligations are not met.
- Competitive pressure from larger pharma entrants and platform competitors that can limit commercial opportunity.
- Limited visibility into near-term cash runway and upcoming milestone timelines given absent EDGAR detail.
- Market sentiment swing away from speculative biotech toward large-cap defensive healthcare, reducing capital flows.
See today's live rating, score and targets
Members see the live hourly rating for KPTI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.